[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier to attend LIVE "Market on Close" program each Friday with John Rowland. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Terns Pharmaceuticals Inc (TERN)

Terns Pharmaceuticals Inc (TERN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 6,116,838
  • Shares Outstanding, K 115,521
  • Annual Sales, $ 0 K
  • Annual Income, $ -96,210 K
  • EBIT $ -110 M
  • EBITDA $ -110 M
  • 60-Month Beta -0.37
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 5.46
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.79
  • Most Recent Earnings $-0.27 on 11/10/25
  • Next Earnings Date 05/14/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 5.21% (-0.59%)
  • Historical Volatility 17.25%
  • IV Percentile 1%
  • IV Rank 0.07%
  • IV High 573.79% on 10/24/25
  • IV Low 4.81% on 04/09/26
  • Expected Move (DTE 7) 0.04 (0.08%)
  • Put/Call Vol Ratio 0.33
  • Today's Volume 387
  • Volume Avg (30-Day) 3,798
  • Put/Call OI Ratio 0.40
  • Today's Open Interest 190,953
  • Open Int (30-Day) 200,646
  • Expected Range 52.91 to 52.99

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 10 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $-0.31
  • Number of Estimates 2
  • High Estimate $-0.29
  • Low Estimate $-0.32
  • Prior Year $-0.26
  • Growth Rate Est. (year over year) -19.23%

Price Performance

See More
Period Period Low Period High Performance
1-Month
52.42 +1.01%
on 04/07/26
52.98 -0.06%
on 05/04/26
+0.23 (+0.44%)
since 04/02/26
3-Month
34.99 +51.35%
on 02/05/26
53.19 -0.45%
on 03/26/26
+16.89 (+46.84%)
since 02/04/26
52-Week
2.65 +1,894.35%
on 05/15/25
53.19 -0.45%
on 03/26/26
+49.45 (+1,412.86%)
since 05/02/25

Most Recent Stories

More News
Merck Completes Acquisition of Terns Pharmaceuticals, Inc.

Addition of TERN-701, a novel investigational oral allosteric BCR::ABL1 tyrosine kinase inhibitor, further diversifies Merck’s oncology pipeline

MRK : 112.30 (-1.11%)
TERN : 52.95 (+0.04%)
Do Wall Street Analysts Like Merck & Co. Stock?

Merck & Co. has outperformed the broader market over the past year, and analysts remain moderately optimistic about the stock’s prospects.

XLV : 144.72 (-0.47%)
$SPX : 7,337.11 (-0.38%)
MRK : 112.30 (-1.11%)
TERN : 52.95 (+0.04%)
Terns Pharmaceuticals Announces FDA Breakthrough Therapy Designation Granted to TERN-701 for Certain Patients with Chronic Myeloid Leukemia

FOSTER CITY, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that the U.S....

TERN : 52.95 (+0.04%)
Merck Announces Expiration of Hart-Scott-Rodino Act Waiting Period to Acquire Terns Pharmaceuticals, Inc.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”),...

MRK : 112.30 (-1.11%)
TERN : 52.95 (+0.04%)
Are TERN, SLNO, WSR Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

WSR : 18.96 (+0.05%)
TERN : 52.95 (+0.04%)
SLNO : 52.95 (+0.02%)
Terns Pharmaceuticals Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Terns Pharmaceuticals, Inc. - TERN

Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti , LLC (“KSF”) are investigating the proposed sale of Terns Pharmaceuticals...

MRK : 112.30 (-1.11%)
TERN : 52.95 (+0.04%)
Are WSR, TERN, RLYB, DAWN Obtaining Fair Deals for their Shareholders?

Insiders may stand to receive substantial financial benefits not available to ordinary shareholders.

RLYB : 14.66 (+0.69%)
WSR : 18.96 (+0.05%)
TERN : 52.95 (+0.04%)
DAWN : 21.53 (+0.19%)
Merck & Co.'s Quarterly Earnings Preview: What You Need to Know

Merck & Co. is expected to unveil its first-quarter results later this month, and analysts are projecting a triple-digit decline in profit.

XLV : 144.72 (-0.47%)
$SPX : 7,337.11 (-0.38%)
MRK : 112.30 (-1.11%)
TERN : 52.95 (+0.04%)
Merck Begins Tender Offer to Acquire Terns Pharmaceuticals, Inc.

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, is commencing today, through a subsidiary, a cash tender offer to purchase all outstanding shares of common stock of Terns Pharmaceuticals,...

MRK : 112.30 (-1.11%)
TERN : 52.95 (+0.04%)
Terns Pharmaceuticals Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(C)(4)

FOSTER CITY, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage oncology company, today announced that it has granted...

TERN : 52.95 (+0.04%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength is above 70%. The market is in overbought territory. Watch for a potential trend reversal.

See More Share

Business Summary

Terns Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It engages in development of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis and other chronic liver diseases. Terns Pharmaceuticals Inc. is based in FOSTER CITY,...

See More

Key Turning Points

3rd Resistance Point 53.01
2nd Resistance Point 53.00
1st Resistance Point 52.97
Last Price 52.95
1st Support Level 52.93
2nd Support Level 52.92
3rd Support Level 52.89

See More

52-Week High 53.19
Last Price 52.95
Fibonacci 61.8% 33.89
Fibonacci 50% 27.92
Fibonacci 38.2% 21.96
52-Week Low 2.65

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.